AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 201 min read$RCKT

Wilson Martin sold $2K of RCKT

Wilson Martin (General Counsel) sold 631 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.38 on 2026-08-18.

Original reporting
SEC EDGAR · Wilson Martin
Published Aug 20, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RCKT
Neutral
high confidence
Mentioned
$RCKT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCKTNeutralLow
01

Why it matters

The sale is modest and unlikely to affect RCKT's valuation, but it adds to the ongoing monitoring of insider behavior.

02

Market read

Routine insider sale with minimal market impact; primarily of interest to insiders‑tracking strategies.

03

What to watch

Potential upcoming regulatory or clinical events not disclosed could influence future insider activity.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filing discloses insider transactions; investors track these for signals.

Company-level read

Ticker impact

$RCKTNeutralHigh confidence
Context

General Counsel Wilson Martin sold 631 shares for $2,133, reducing his holdings to 673,853 shares.

Expected impact

Minimal downward pressure, likely negligible impact on stock price.

Evidence & confidence

The transaction size is trivial relative to market cap and insider holdings, so market reaction should be muted.

Market effects

Sector

No broader sector impact; the sale is company‑specific and small.

Regional

None; limited to US biotech market.

Global

Insignificant on a global scale.

Counterpoint

What could challenge this read

Even small insider sells can signal concerns; monitor for further disposals.

Key entities

  • person
    Wilson Martin

    General Counsel of Rocket Pharmaceuticals, Inc.

  • company
    Rocket Pharmaceuticals, Inc.

    Biopharmaceutical company developing therapies for rare diseases.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCKT insider trading history →

Related articles

SEP 4
$RCKTHighAI 9/10

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

Rocket Pharmaceuticals (RCKT) shares fell 22% despite FDA approval of its gene therapy Kresladi for a rare pediatric disorder. The company received a Rare Pediatric Disease Priority Review Voucher. Analysts from Wedbush and LifeSci Capital maintained 'Outperform' ratings, citing the milestone and potential financial benefits. RCKT stock has dropped 53% in the past year.

stocktwits.com2 min
SEP 2
$RCKTMedAI 8/10

Rocket amended complaint alleges UWM targeted Mr. Cooper borrowers

Rocket amended its complaint against UWM, alleging UWM breached agreements by targeting Mr. Cooper borrowers for refinancing, causing prepayment rates 2.5x higher. Rocket claims $100M in damages, citing UWM's initiatives like Refi75 and KEEP. UWM denies allegations, calling them baseless. Rocket acquired Mr. Cooper for $14.2B in 2025.

housingwire.com3 min
AUG 10
$RCKTMed

ROCKET PHARMACEUTICALS, INC. (RCKT): Results of Operations and Financial Condition

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic mic

SEC EDGAR 8-K6 min
AUG 4
$RCKTMed

Rocket points to Danon gene therapy’s safety after Phase II protocol change

Rocket Pharmaceuticals said its RP-A501 Danon disease gene therapy has safely treated three Phase II patients after an FDA-triggered protocol change. The FDA allowed relaunch of NCT06092034 in Aug 2025. Rocket reports no capillary leak syndrome, blood vessel damage, or other serious adverse events since dosing with a recalibrated dose plus rituximab, sirolimus, and corticosteroids.

yahoo.com5 min
AUG 3
$RCKTMed

Why is Rocket Pharmaceuticals stock volatile today?

Investing.com reports Rocket Pharmaceuticals (RCKT) rose 0.6% pre-open after it said the first three patients treated under a revised Phase 2 protocol for RP-A501 Danon disease gene therapy showed no significant safety issues, including no thrombotic microangiopathy or capillary leak syndrome. The FDA lifted the clinical hold in mid-2025. Shares were $3.13 ahead of Aug 6 Q2 2026 earnings.

investing.com3 min
JUN 12
$RCKTMed

ROCKET PHARMACEUTICALS, INC. (RCKT): Completion of Acquisition or Disposition of Assets

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001281895 0001281895 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2026 R

SEC EDGAR 8-K2 min